Idiopathic pulmonary fibrosis: current and future directions

Soo, Eleanor; Adamali, Huzaifa; Edey, Anthony

doi:10.1016/j.crad.2016.12.014

Cited by 8 publications

(5 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathogenesis of IPF has not yet been elucidated, and anti-inflammatory therapy is generally used clinically with glucocorticoids, immunosuppressants, cytotoxic agents or inhibitor (Pirfenidone and Nintedanib) ( 7 – 9 ). With the deepening of clinical research, researchers found that only 20% of IPF patients are sensitive to glucocorticoid therapy, and often transgender reactions(allergies: it is a type of immune reaction, a reaction that occurs after non-peptide drugs are combined with the body’s protein as a hapten to an antigen), there is no specific treatment plan for IPF in the clinic, coupled with the lack of specific clinical manifestations in the early stage of IPF, so the difficulty of diagnosis and treatment is high ( 10 , 11 ). In recent years, it has been found that IPF often presents familial aggregation, suggesting that it may be a polygenic co-acting diseases.…”

Section: Introductionmentioning

confidence: 99%

Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies

Dai

Yang²,

Zhang³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

ObjectiveThe study aims to identify potential diagnostic markers of idiopathic pulmonary fibrosis (IPF) and analyze the significance of immune cell infiltration in this pathology.Materials and methodsDownload two publicly available gene expression profiles (GSE10667 and GSE24206 datasets) from the GEO database including 48 Idiopathic pulmonary fibrosis (IPF) samples and 21 human control samples and select for distinctly expressed genes (DEG) from them. Lasso regression model and support vector machine recursive feature elimination S,V,R,F analysis were used to check candidate biomarkers. The area under the subject’s work characteristic curve (AUC) value is used to evaluate its recognition ability. The GSE53845 dataset (40 IPF patients and 8 controls) continue to validate the expression level and diagnostic value of biomarkers in IPF. Comprehensive analysis of immune infiltrated cells of IPF was performed using R software and immune cell infiltration estimation analysis tool- deconvolution algorithm (CIBERSORT).Results43 DEGs were identified in total. The identified DEGs mostly involve pneumonia, lung disease, collagen disease, obstructive pulmonary disease and other diseases. The activation of IL-17 signaling pathways, amoebic disease, interaction of viral proteins with cytokines and cytokine receptors, protein digestion and absorption, and flaccid hormone signaling pathways in IPF were different from the control group. The expression degree of CRTAC1, COL10A1, COMP, RPS4Y1, IGFL2, NECAB1, SCG5, SLC6A4, and SPP1 in IPF tissue were prominently higher than the normal group. Immune cell infiltration analysis showed that CRTAC1, COL10A1, COMP, IGFL2, NECAB1, SCG5, SLC6A4, and SPP1 were associated with monocytes, plasma cells, neutrophils, and regulatory (treg) T cells.ConclusionCRTAC1, COL10A1, COMP, IGFL2, NECAB1, SCG5, SLC6A4, and SPP1 can be used as diagnostic markers for IPF, providing new ideas for the future study of IPF occurrence and molecular mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies

Dai

Yang²,

Zhang³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…IPF is the most widely recognized sort of idiopathic interstitial pneumonia. Although the ailment has been viewed as uncommon, it happens with comparable recurrence to that of stomach, mind, and testicular diseases [2,3]. Solid tissue is supplanted by the adjusted extracellular grid and alveolar engineering is obliterated, which prompts diminished lung consistency, upset gas trade, and at last respiratory disappointment and passing [4].…”

Section: Idiopathic Pulmonary Fibrosis (Ipf)mentioning

confidence: 99%

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Dudhat

Patel

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the model of a substantial and heterogeneous gathering of pneumonic issues, mostly constant and dynamic, normally known as interstitial lung disease. In the course of the most recent couple of decades, IPF has been progressively perceived as a noteworthy neglected therapeutic need in respiratory pharmaceutical and has turned into the focal point of exceptional research action. This is because of the ways that IPF frequency is expanding around the world, with rates (and sadly forecast) that are fundamentally the same as those of numerous types of growth. Clinical research on IPF has been gigantically progressing, coming full circle in the current revelation of two sheltered and compelling medications, now at long last made accessible to patients. Ordinary treatment for lung disease is related to the absence of specificity and access to the typical cells bringing about cytotoxicity, lessened cell take-up, tranquilize obstruction, and quick medication freedom from the body. The rise of nanotechnology has reformed the treatment of lung diseases like IPF. The focal point of nanotechnology is to target abnormal alveolar epithelial cells (AECs) with enhanced bioavailability and diminished poisonous quality. Nanoparticulates have the potential for IPF treatment by increasing particular access to the abnormal AECs because of surface modifiability and littler size. This audit article additionally features the attributes, ongoing advances in the planning of NPs, and helpful results.

show abstract

“…A weak forecasting at baseline in CFA is important to lead the timely referral for lung transplantation and this information can be collected by characterization of indicators that are strongly associated with later stages of CFA [10]. In actual sense, cohort enhancement strategies used in CFA drug trail settings can decrease the sample sizes, and reduction in the restrictive costs with respect to the clinical trials can be achieved [11] by forecasting the patients prone to experience increased clinical events [12].…”

Section: Introductionmentioning

confidence: 99%

Association Between Pulmonary Vessel-Related Structures and Cryptogenic Fibrosing Alveolitis Using Derived Computed Tomography Among Chinese Patients

2019

Med Sci Monit

View full text Add to dashboard Cite

Background The aim of this study was to assess the association between pulmonary vessel-related structures and cryptogenic fibrosing alveolitis (CFA) in a drug trial in a Chinese population using derived computed tomography (dCT) to evaluate functional reduction and survival. Material/Methods Discovery and validation cohorts were chosen separately by fulfilment of drug trial entry criteria, and we enrolled 269 and 292 consecutive patients, respectively. CFA patients who had undergone imaging based on volumetric non-contrast CT at our hospital were subjected to pulmonary vessel-related structure (PVS) measures and dCT to forecast mortality and reduction in reduced forced vital capacity of CFA. Results The best forecaster of survival and reduction in terms of reduced forced vital capacity were found to be the dCT-generated outcomes in terms of PVS scores. Patients having less extensive disease highlighted the dCT outcomes through outperformance of CFA measures. When we used the cohort enhancement device, we found reduction in the requisite sample size of a CFA drug trial by 31% with the use of more than 5.0% dCT PVS score. Conclusions We found an association between CFA and PVS using dCT and it is far better than the results achieved so far by use of criterion standard measures. Additionally, reduction in the restrictive trial costs was also achieved by using cohort enhancement in a CFA drug trial setting, as PVS scores forced us to decrease the size of required CFA drug trial population by 30%. Interestingly, patients who had to take antifibrotic medication for longer periods had longer survival and less decreases forced vital capacity, as identified by PVS scores.

show abstract

Idiopathic pulmonary fibrosis: current and future directions

Cited by 8 publications

References 105 publications

Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies

Identification of diagnostic gene biomarkers related to immune infiltration in patients with idiopathic pulmonary fibrosis based on bioinformatics strategies

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Association Between Pulmonary Vessel-Related Structures and Cryptogenic Fibrosing Alveolitis Using Derived Computed Tomography Among Chinese Patients

Contact Info

Product

Resources

About